Dianthus Therapeutics, Inc.

NASDAQ:DNTH

Biotechnology

Healthcare
$83.98 -1.25%

-$1.03 today

Market cap
$4.73B
Beta
0.07
P/E (TTM)
-343.0
EPS (TTM)
-$0.24
52W Low $16.64High $96.50

Volume 0.84M

Average 0.82M

DNTH Debt Repayment

Cash used to repay borrowings during the period.

Dianthus Therapeutics, Inc.NASDAQ: DNTH

Debt Repayment · Q2 FY2026 · quarter ended Jun 2026

Debt repayment outflow grows to $0

Q2 FY2026 debt repayment was $0, compared with $0 a year earlier. Trailing-twelve-month debt repayment was $0.

Context

  • Debt repayment amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Debt repayment increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
$0— YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Debt Repayment vs competitors

How DNTH compares with its peers on the latest reported figures

  • DNTH's LTM Jun 2026 debt repayment of $0 is the 5th largest of the 10 companies compared; the peer median is $0.
  • Debt repayment amounts to 0.0% of revenue for DNTH, versus a peer median of 0.0%.
DNTH Competitors Peer median
Debt Repayment for DNTH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$66.6M +147.6%—28.7%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$24.47M -66.5%——
QTTBQ32 Bio Inc.LTM Mar 2026$4.69M ——8.7%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$66K -63.7%——
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$0 ——0.0%
IMVTImmunovant, Inc.LTM Sep 2026$0 ——0.0%
VERAVera Therapeutics, Inc.LTM Jun 2026$0 —+5.6%—
ALMSAlumis Inc. Common StockLTM Jun 2026$0 ——0.0%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
CNTBConnect Biopharma Holdings LimitedFY2025$0 ——0.0%
Peer median (excluding DNTH) $0-63.7%+5.6%0.0%

Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.14M)(28.48M)(43.56M)(84.97M)(162.34M)
Depreciation & Amortization2.02M147K355K412K428K
Deferred Income Tax00(661K)00
Stock-Based Compensation01.52M2.9M12.89M22.79M
Change in Working Capital(1.53M)(1.65M)4.86M(351K)16.73M
Accounts Receivables0(4.16M)5.16M0755K
Inventory00000
Accounts Payables(720K)2.28M661K8.19M11.28M
Other Working Capital(806K)229K(959K)(8.54M)4.69M
Other Non-Cash Items11.11M(606K)(762K)(6.17M)(6.67M)
Operating Cash Flow(59.53M)(29.07M)(36.86M)(78.18M)(129.06M)
Capital Expenditures(1.26M)(139K)(110K)(105K)(213K)
Acquisitions (Net)00000
Purchases of Investments(45.31M)(61.68M)(57.42M)(413.71M)(435.01M)
Sales of Investments90M2M77.79M127M312.39M
Other Investing Activities00000
Investing Cash Flow43.43M(59.82M)20.25M(286.81M)(122.83M)
Debt Repayment00000
Common Stock Issued89.6M072M269.2M280.13M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(3.32M)61.57M(13.58M)0
Financing Cash Flow89.6M96.68M133.57M255.62M280.13M
Effect of Forex Changes00000
Net Change in Cash73.5M7.79M116.97M(109.37M)28.23M
Free Cash Flow(60.8M)(29.21M)(36.97M)(78.29M)(129.27M)

Dianthus Therapeutics, Inc.

NASDAQ:DNTH

Intrinsic Alpha fair value

Locked

Current Price

$83.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.